Literature DB >> 22552602

Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.

Yagob Al-Mazrou1, Mohamed Khalil, Helen Findlow, Helen Chadha, Valerie Bosch Castells, David R Johnson, Ray Borrow.   

Abstract

Reduced immune responses to repeated polysaccharide vaccination have been previously reported, but there are limited immunogenicity data on the use of meningococcal polysaccharide vaccine (PSV) followed by meningococcal conjugate vaccine. Saudi Arabian adolescents (aged 16 to 19 years) who had previously been vaccinated with ≥1 dose of bivalent meningococcal polysaccharide vaccine and 1 dose of quadrivalent meningococcal polysaccharide (MPSV4) were enrolled in a controlled, randomized, and modified observer-blind study (collectively termed the PSV-exposed group). The PSV-exposed group was randomized to receive either quadrivalent meningococcal conjugate vaccine (MCV4) (n = 145 PSV-exposed/MCV4 group) or MPSV4 (n = 142 PSV-exposed/MPSV4 group), and a PSV-naïve group received MCV4 (n = 163). Serum samples collected prevaccination and 28 days postvaccination were measured by baby rabbit serum bactericidal antibody (rSBA) assay, and vaccine tolerability and safety were also evaluated. For each serogroup, the postvaccination geometric mean titers (GMTs) were significantly higher in the PSV-naïve group than in either group comprised of the PSV-exposed participants. The postvaccination serogroup C rSBA GMT was significantly higher in the PSV-MCV4 group than in the PSV-MPSV4 group after adjusting for prevaccination GMTs. Although not statistically significant, similar differences were observed for serogroups A, Y, and W-135. No worrisome safety signals were detected. This study demonstrated MCV4 to be safe and immunogenic in those who had previously received polysaccharide vaccination, and it suggests that conjugate vaccine can partially compensate for the hyporesponsiveness seen with repeated doses of polysaccharide vaccine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552602      PMCID: PMC3393373          DOI: 10.1128/CVI.00039-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  13 in total

1.  Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2002-10-04

2.  Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults.

Authors:  Raman Lakshman; Roger Burkinshaw; Sharon Choo; Adam Finn
Journal:  Vaccine       Date:  2002-11-01       Impact factor: 3.641

3.  Pilgrimage to Mecca (Hajj) 1992.

Authors: 
Journal:  Commun Dis Rep CDR Wkly       Date:  1992-03-06

4.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

Authors:  Harry Keyserling; Thomas Papa; Katalin Koranyi; Robert Ryall; Ehab Bassily; Michael J Bybel; Kevin Sullivan; Gregory Gilmet; Al Reinhardt
Journal:  Arch Pediatr Adolesc Med       Date:  2005-10

5.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

6.  Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults.

Authors:  R Borrow; H Joseph; N Andrews; M Acuna; E Longworth; S Martin; N Peake; R Rahim; P Richmond; E Kaczmarski; E Miller
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

7.  Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

Authors:  R Gold; M L Lepow; I Goldschneider; T L Draper; E C Gotschlich
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

8.  Changes in epidemiological pattern of Meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control?

Authors:  Yagob Y Al-Mazrou; Mohamed H Al-Jeffri; Mohamed N Abdalla; Sirag A Elgizouli; Amin A Mishskas
Journal:  Saudi Med J       Date:  2004-10       Impact factor: 1.484

9.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Oleg O Bilukha; Nancy Rosenstein
Journal:  MMWR Recomm Rep       Date:  2005-05-27

10.  Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.

Authors:  Hani Jokhdar; Ray Borrow; Abdulrazaq Sultan; Mousaed Adi; Christine Riley; Emily Fuller; David Baxter
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more
  2 in total

1.  Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.

Authors:  Ghassan Dbaibo; Nabil El-Ayoubi; Soha Ghanem; Farah Hajar; Veronique Bianco; Jacqueline M Miller; Narcisa Mesaros
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

2.  Different Long-Term Duration of Seroprotection against Neisseria meningitidis in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands.

Authors:  Milou Ohm; Debbie M van Rooijen; Axel A Bonačić Marinović; Mariëtte B van Ravenhorst; Marieke van der Heiden; Anne-Marie Buisman; Elisabeth A M Sanders; Guy A M Berbers
Journal:  Vaccines (Basel)       Date:  2020-10-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.